Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target

The primary effector of cGMP signaling in Plasmodium is the cGMP-dependent protein kinase (PKG). Work in human-infective Plasmodium falciparum and rodent-infective Plasmodium berghei has provided biological validation of P. falciparum PKG (PfPKG) as a drug target for treating and/or protecting again...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotella, David, Siekierka, John, Bhanot, Purnima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886688/
https://www.ncbi.nlm.nih.gov/pubmed/33613463
http://dx.doi.org/10.3389/fmicb.2020.610408
_version_ 1783651848906866688
author Rotella, David
Siekierka, John
Bhanot, Purnima
author_facet Rotella, David
Siekierka, John
Bhanot, Purnima
author_sort Rotella, David
collection PubMed
description The primary effector of cGMP signaling in Plasmodium is the cGMP-dependent protein kinase (PKG). Work in human-infective Plasmodium falciparum and rodent-infective Plasmodium berghei has provided biological validation of P. falciparum PKG (PfPKG) as a drug target for treating and/or protecting against malaria. PfPKG is essential in the asexual erythrocytic and sexual cycles as well as the pre-erythrocytic cycle. Medicinal chemistry efforts, both target-based and phenotype-based, have targeted PfPKG in the past few years. This review provides a brief overview of their results and challenges.
format Online
Article
Text
id pubmed-7886688
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78866882021-02-18 Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target Rotella, David Siekierka, John Bhanot, Purnima Front Microbiol Microbiology The primary effector of cGMP signaling in Plasmodium is the cGMP-dependent protein kinase (PKG). Work in human-infective Plasmodium falciparum and rodent-infective Plasmodium berghei has provided biological validation of P. falciparum PKG (PfPKG) as a drug target for treating and/or protecting against malaria. PfPKG is essential in the asexual erythrocytic and sexual cycles as well as the pre-erythrocytic cycle. Medicinal chemistry efforts, both target-based and phenotype-based, have targeted PfPKG in the past few years. This review provides a brief overview of their results and challenges. Frontiers Media S.A. 2021-02-03 /pmc/articles/PMC7886688/ /pubmed/33613463 http://dx.doi.org/10.3389/fmicb.2020.610408 Text en Copyright © 2021 Rotella, Siekierka and Bhanot. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Rotella, David
Siekierka, John
Bhanot, Purnima
Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target
title Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target
title_full Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target
title_fullStr Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target
title_full_unstemmed Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target
title_short Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target
title_sort plasmodium falciparum cgmp-dependent protein kinase – a novel chemotherapeutic target
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886688/
https://www.ncbi.nlm.nih.gov/pubmed/33613463
http://dx.doi.org/10.3389/fmicb.2020.610408
work_keys_str_mv AT rotelladavid plasmodiumfalciparumcgmpdependentproteinkinaseanovelchemotherapeutictarget
AT siekierkajohn plasmodiumfalciparumcgmpdependentproteinkinaseanovelchemotherapeutictarget
AT bhanotpurnima plasmodiumfalciparumcgmpdependentproteinkinaseanovelchemotherapeutictarget

Ejemplares similares